Navigation Links
TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011
Date:3/11/2011

CHENGDU, China, March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals is invited to present at the 23rd ROTH Annual OC Growth Stock Conference from March 13 - 16, 2011 at the Ritz Carlton in Dana Point, California.

Dr. James Jiayuan Tong, Chief Financial Officer, Chief Business & Development Officer and Board Director of the Company will present at 8:30 am, March 16, at track 2 of the Conference.

An updated Company's presentation can be found on the Investors Relations of www.tianyinpharma.com

About TPITPI, headquartered at Chengdu, China, is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical medicine, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

More information regarding the Company can be found at: http://www.tianyinpharma.com.

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc.Web:
http://www.tianyinpharma.comEmail:   Dr.Tong@tianyinpharma.comTel:
+86-28-8551-6696 (Chengdu, China)+86-134-3655-0011 (China)+1-949-350-6999 (U.S.)Address: 23rd Floor Unionsun Yangkuo PlazaNo 2 Block 3 South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Attends North American Bio Forum at Canadian Government Invitation
2. US Oncology Clinical Development Attends Partnerships With CROs
3. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. UBM Announces Content for 10th Annual Japanese Pharma & Bio Events
5. 6th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Beatrice Mintz, Ph.D.
6. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
7. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
8. BioSpecifics Technologies Corp. to Present at Cowen and Company 31st Annual Health Care Conference
9. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
10. Huifeng Bio-Pharmaceutical Technology, Inc. to Present at the 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai
11. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity ... intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers at ... result of a collaboration among several companies with expertise in toolholding, cutting tools, ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):